Study on Anti-MCV Antibodies and Arthritis Activity
Author Information
Author(s): Ursum Jennie, Nielen Markus MJ, van Schaardenburg Dirkjan, van der Horst Ann R, van de Stadt Rob J, Dijkmans Ben AC, Hamann Dörte
Primary Institution: Jan van Breemen Institute
Hypothesis
The study aimed to investigate the association between arthritic disease activity and antibodies to mutated citrullinated vimentin (anti-MCV).
Conclusion
The correlation between anti-MCV levels and parameters of disease activity was very low, indicating that monitoring disease activity with anti-MCV levels is not useful.
Supporting Evidence
- Anti-MCV levels and DAS28 exhibited a significant decrease during the first and second year.
- Anti-MCV had a specificity of 92.3% and a sensitivity of 59.3%.
- Anti-MCV-positive patients had higher disease activity scores at 2 years of follow up.
Takeaway
The study looked at how a specific antibody relates to arthritis activity, and found that it doesn't really help doctors track how active the disease is.
Methodology
Anti-MCV levels were measured in patients with early arthritis at baseline and at 1 and 2 years of follow up, while disease activity was assessed using the Disease Activity Score based on 28 joints (DAS28).
Limitations
The study did not find a substantial association between anti-MCV levels and disease activity, suggesting limitations in using anti-MCV for monitoring.
Participant Demographics
162 patients with early arthritis, including 123 with rheumatoid arthritis and 39 with undifferentiated arthritis.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website